Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).

Li Y, Li L, De Peng Y, Song GY, Ye SD, Du LY, Hou JN, Ji QH

Diabetes therapy : research, treatment and education of diabetes and related disorders21 Jun 2019Cited by 14 (Europe PMC)

PMID31228090PMCIDPMC6612357DOI10.1007/s13300-019-0646-yPepBankPUB-31228090

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese T2DM patients, dulaglutide 1.5 mg reduced HbA1c more than glargine at week 26.
In plain wordsIn Chinese T2DM patients, dulaglutide 1.5 mg reduced HbA1c more than glargine at week 26.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.67%
dulaglutide 1.5 mg
HbA1c difference
−0.56%
dulaglutide 1.5 mg versus glargine
HbA1c change
−1.11%
glargine
Source sentences
Summary
At week 26, the least squares mean (LSM) change from baseline in HbA1c was greater with dulaglutide 1.5 mg (- 1.67%) and dulaglutide 0.75 mg (- 1.31%) compared with glargine (- 1.11%). The LSM (95% confidence interval) for the difference of dulaglutide 1.5 mg and 0.75 mg vs glargine was - 0.56% (- 0…
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809001
02HumanRandomized controlled trialEfficacy outcome
In Chinese T2DM patients, dulaglutide groups had greater body weight reductions than the glargine group.
In plain wordsIn Chinese T2DM patients, dulaglutide groups lost more weight than the glargine group.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 607
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The mean body weight decreased (P < 0.001) and total hypoglycemia rates were lower (P < 0.05) in the dulaglutide groups compared with the glargine group.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809005
03HumanRandomized controlled trialSafety outcome
In Chinese T2DM patients, total hypoglycemia rates were lower with dulaglutide than glargine.
In plain wordsIn Chinese T2DM patients, low blood sugar occurred less often with dulaglutide than glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTotal hypoglycemia
Study
n = 607
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The mean body weight decreased (P < 0.001) and total hypoglycemia rates were lower (P < 0.05) in the dulaglutide groups compared with the glargine group.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809006
04HumanRandomized controlled trialEfficacy outcome
In Chinese T2DM patients, dulaglutide 0.75 mg reduced HbA1c more than glargine at week 26.
In plain wordsIn Chinese T2DM patients, dulaglutide 0.75 mg reduced HbA1c more than glargine at week 26.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.31%
dulaglutide 0.75 mg
HbA1c difference
−0.2%
dulaglutide 0.75 mg versus glargine
HbA1c change
−1.11%
glargine
Source sentences
Summary
At week 26, the least squares mean (LSM) change from baseline in HbA1c was greater with dulaglutide 1.5 mg (- 1.67%) and dulaglutide 0.75 mg (- 1.31%) compared with glargine (- 1.11%). The LSM (95% confidence interval) for the difference of dulaglutide 1.5 mg and 0.75 mg vs glargine was - 0.56% (- 0…
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809002
05HumanRandomized controlled trialEfficacy outcome
In Chinese T2DM patients, dulaglutide 1.5 mg was noninferior and superior to glargine for HbA1c at 52 weeks.
In plain wordsIn Chinese T2DM patients, dulaglutide 1.5 mg reduced HbA1c more than glargine at 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c noninferiority and superiority
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Both doses of dulaglutide were noninferior and superior to glargine at 26 weeks and 52 weeks (two-sided P value < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809003
06HumanRandomized controlled trialEfficacy outcome
In Chinese T2DM patients, dulaglutide 0.75 mg was noninferior and superior to glargine for HbA1c at 52 weeks.
In plain wordsIn Chinese T2DM patients, dulaglutide 0.75 mg reduced HbA1c more than glargine at 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c noninferiority and superiority
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Both doses of dulaglutide were noninferior and superior to glargine at 26 weeks and 52 weeks (two-sided P value < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809004
07HumanRandomized controlled trialSafety outcome
In Chinese T2DM patients, gastrointestinal events were the most frequently reported adverse events in dulaglutide groups.
In plain wordsIn Chinese T2DM patients, stomach and bowel events were the most common adverse events in dulaglutide groups.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Gastrointestinal adverse events (AEs) were the most frequently reported AEs in dulaglutide groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a subgroup analysis of a phase 3, open-label, randomized, parallel-arm, 52-week study in Chinese patients aged ≥ 18 years with T2DM who had inadequate glycemic control with OAMs (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤ 11.0%).
Summary · context
A total of 607 patients from China were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or once-daily glargine.
Report a problemFND-3122809007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.